

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
 US Department of Commerce  
 United States Patent and Trademark  
 Office, PCT  
 2011 South Clark Place Room  
 CP2/5C24  
 Arlington, VA 22202  
 ETATS-UNIS D'AMERIQUE  
 in its capacity as elected Office

Date of mailing (day/month/year) 06 November 2001 (06.11.01)	
International application No. PCT/GB00/02841	Applicant's or agent's file reference P022293WO
International filing date (day/month/year) 21 July 2000 (21.07.00)	Priority date (day/month/year) 23 July 1999 (23.07.99)
Applicant SNAPE, Mike et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
 22 February 2001 (22.02.01)

☐ in a notice effecting later election filed with the International Bureau on:  
 \_\_\_\_\_

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Zakaria EL KHODARY Telephone No.: (41-22) 338.83.38
---	--

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
1 February 2001 (01.02.2001)

PCT

(10) International Publication Number  
**WO 01/07023 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/00**
- (21) International Application Number: **PCT/GB00/02841**
- (22) International Filing Date: **21 July 2000 (21.07.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
9917386.6      23 July 1999 (23.07.1999)      GB
- (71) Applicant (for all designated States except US): **VERNALIS RESEARCH LIMITED** [GB/GB]; Oakdene Court, 613 Reading Road, Winnersh, Wokingham RG41 5UA (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SNAPE, Mike** [GB/GB]; Oakdene Court, 613 Reading Road, Winnersh, Wokingham RG41 5UA (GB). **MONCK, Nathaniel, Julius** [GB/GB]; Oakdene Court, 613 Reading Road, Winnersh, Wokingham RG41 5UA (GB). **FLETCHER, Allan** [GB/GB]; Oakdene Court, 613 Reading Road, Winnersh, Wokingham RG41 5UA (GB). **STANHOPE, Kelly, Jean** [GB/GB]; Oakdene Court, 613 Reading Road, Winnersh, Wokingham RG41 5UA (GB). **MANSELL, Howard, Langham** [GB/GB]; Oakdene Court, 613 Reading Road, Winnersh, Wokingham RG41 5UA (GB).
- (74) Agents: **HOWARD, Paul, Nicholas et al.**; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **CHEMICAL COMPOUNDS-II**



(57) Abstract: Use of a compound of formula (I) wherein: R<sup>1</sup> is aryl; R<sup>2</sup> is H, alkyl or aryl; and R<sup>3</sup> is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for neuroprotection in a subject or for the treatment of cerebral ischaemia, central nervous system injury or eye diseases.

WO 01/07023 A2

## CHEMICAL COMPOUNDS - II

The present invention relates primarily to neuroprotection and to the treatment of stroke and other cerebrovascular disorders.

5

Stroke and other acute brain injuries are major causes of mortality and morbidity in the adult population. Stroke is the third highest cause of death in major industrialised countries and the commonest cause of permanent disability. Each year, in the US and Europe, approximately 1 million people suffer an acute stroke. Between 25% and 35% of these patients die within the first three weeks, and of the survivors 25% to 50% will be totally dependant on family or institutional care for the rest of their lives. The incidence of stroke increases with age, roughly doubling with each passing decade, with 30% of persons aged over 65 years being affected.

15 The statistics for stroke translate into an annual incidence of 0.1 to 0.2% in the US and Europe, with the world-wide market for stroke estimated to be worth \$3 billion in 1995 and projected to rise to \$10 billion in 2005. There is an unmet medical need for a cytoprotective therapy for stroke.

20 No effective neuroprotectant therapy is presently available for cerebrovascular disorders. The only therapy currently licensed for the treatment of ischaemic stroke is Genetech's thrombolytic recombinant tissue plasminogen activator (Activase®, rtPA; Alteplase). Activase is indicated for the management of acute ischaemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment with Activase should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial haemorrhage by a cranial computerised tomography (CT) scan or other diagnostic imaging method sensitive for the presence of haemorrhage.

25 The mechanisms underlying the irreversible brain damage which occurs following ischaemia are complex. Many classes of compounds are currently under investigation as treatments for cerebrovascular disorders. Acute intervention with both cytoprotective (neuroprotective) and other thrombolytic agents is undergoing active investigation.

Cytoprotective neuroprotective therapy includes drugs that act to prevent cell death during ischaemia and reperfusion. These agents include calpain inhibitors, voltage-sensitive calcium- and sodium-channel antagonists, receptor-mediated calcium-channel antagonists [including *N*-methyl-D-aspartate (NMDA) and  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) antagonists], glutamate-synthesis inhibitors, glutamate-release antagonists,  $\gamma$ -aminobenzoic acid (GABA) antagonists, 5-HT (serotonin) receptor agonists, gangliosides, antioxidants, growth factors, antiapoptotic agents, and antiadhesion molecules (Silver, B., Weber, J., Fisher, M., *Clin. Neuropharmacol.* 1996, 19, 101-128).

- 10 Excitotoxicity is a major determinant of neuronal death following the induction of cerebral ischaemia. Repetitive cell firing, persistent depolarisation and induction of supra-normal ionic flux across excitable membranes can initiate fatal cellular compromise *via* a variety of synergistic mechanisms during hypoxic excitotoxicity. Control of the state of excitability of neurons depends upon the net balance of excitatory and inhibitory influences  
15 acting on that neurone.

In general, the primary excitatory influence impinging on neurones is mediated by the glutamatergic system, whilst primary inhibition is frequently determined by GABAergic innervation, since the main endogenous inhibitory amino acid in mammalian brain is  
20 GABA. Thus increasing the inhibitory effect of GABAergic innervation, and decreasing the excitatory influence of glutamate, will reduce the net excitation of a neurone. Reducing excitation will reduce the consequences of energy depletion due to hypoxia and promote the ability of the neurone to survive hypoxic cerebral ischaemia.

- 25 Relatively few of the drugs currently under investigation as neuroprotectants for the treatment of stroke and other cerebrovascular disorders are modulators of the endogenous inhibitory amino acid, GABA.

One class of molecules which apparently possess neuroprotective properties is the GABA  
30 uptake inhibitors such as CI-966, which was shown to be effective in a gerbil ischaemia model utilising global cerebral ischaemia of 5 min. duration (Phillis, J.W., *Gen. Pharmacol.* 1995, 26, 1061-1064).

The benzodiazepine receptor agonist diazepam has been shown to possess some neuroprotective properties (Karle, J., Witt, M. R., Nielsen, M., *Brain Res.* **1997**, *765*, 21-29).

- 5 In rabbits with reversible spinal cord ischaemia, treatment with muscimol, a reference GABA<sub>A</sub> agonist, at 5 mg/kg significantly prolonged P<sub>50</sub> time, where P<sub>50</sub> represents the duration associated with 50% probability of resultant permanent paraplegia (Madden, K.P., *Stroke*, **1994**, *25*, 2271-2275).
- 10 Felbamate, an antiepileptic drug with *inter alia* GABA agonist properties, provided significant neuronal protection when administered both before and after ischaemia in all regions of the brain in the gerbil model of transient forebrain ischaemia. Protection was moderate when felbamate was used before ischaemia, but was highly significant when felbamate was given 30 min. after the insult. The structural protection with felbamate was
- 15 very significant when used in the post-ischaemic period (Shuaib, A., Waqaar, T., Ijaz, M.S., Kanthan, R., Wishart, T., Howlett, W., *Brain Res.* **1996**, *727*, 65-70).

- Piracetam is a derivative of GABA, and was the first commercially available nootropic drug. Although widely evaluated in the treatment of senile cognitive disorders and
- 20 dyslexia, piracetam has also been assessed as a treatment for deficits associated with acute stroke. Data from a number of small, short term studies in patients treated within a few days of stroke suggest that piracetam is more effective than placebo for the treatment of functional deficits (Noble, S., Benfield, P., *CNS Drugs* **1998**, *9*, 497-511).

- 25 Some combination neuroprotectant therapies have been investigated in rodent ischaemia since the excitotoxic effects of glutamate can be blocked almost completely with GABA in cell culture, tissue slices, and in some animal models. On this basis a combination of muscimol and MK 801, an NMDA receptor antagonist, was investigated and shown to be effective (Lyden, P.D., Lonzo, L., *Stroke* **1994**, *25*, 189-196).

30

WO-A-99/25353 discloses the use of triazolo[4,3-b]pyridazine derivatives as benzodiazepine/GABA<sub>A</sub> modulators for the treatment of psychotic disorders and neurodegeneration.

WO-A-90/09174 discloses the use of the GABAergic agent Clomethiazole (chlormethiazole) in the prevention and/or treatment of neurodegeneration. Clomethiazole is thought to act through a GABAergic pathway, whereby it augments GABA's inhibitory effect on the CNS, giving the drug both hypnotic and neuroprotectant properties.

The clinical neuroprotectant profile of clomethiazole has been reviewed (Muckle, H., *IDrugs* 1999, 2, 184-193). A large-scale phase III trial has been completed in which clomethiazole was evaluated for its ability to reduce nerve damage in acute cerebrovascular ischaemia. A subgroup of patients who presented with large stroke, experienced a significant benefit. Of these (n = 545), 41% of treated patients were functionally independent after 90 days, compared to 30% of patients on placebo.

The effectiveness of this GABA modulator in rat (Snape, M.F., Baldwin, H.A., Cross, A.J., Green, A.R., *Neuroscience* 1993, 53, 837-844) and gerbil ischaemia (Cross, A.J., Jones, J.A., Baldwin, H.A., Green, A.R., *Br. J. Pharmacol.* 1991, 104, 406-411) has been demonstrated. The dose in the latter paradigm was 100 mg/kg, i.p.


Azetidine-1-carboxamides and the use of these compounds in the treatment of anxiety and all forms of epilepsy is described in International Patent Applications Nos. PCT/GB99/00224, PCT/GB99/00219 and PCT/GB99/00223.

There remains a medical need for new treatments for stroke and cerebrovascular disorders. The object of the present invention is to provide such treatments.

25

It has now been found that certain azetidine-1-carboxamides show unexpected neuroprotectant efficacy when compared to reference GABAergic agents. In particular, certain azetidine-1-carboxamides have been shown to potentiate the action of GABA in inhibiting neurones, and have also been shown to prevent the repetitive firing induced as a consequence of activation of glutamatergic mechanisms. Such compounds are found to be neuroprotective following acute cerebral ischaemia in rats and mice, and reduced ischaemia-induced CNS damage in *in vivo* models of focal ischaemia in both species.

According to the present invention, there is provided use of a compound of formula (I)



wherein:

R<sup>1</sup> is aryl;

5 R<sup>2</sup> is H, alkyl or aryl; and

R<sup>3</sup> is hydrogen or alkyl;

or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for neuroprotection in a subject or for the treatment of cerebral ischaemia, central nervous system injury or eye diseases.

10

Reference in the present specification to an "alkyl" group means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl (including allyl) or alkynyl (including propargyl)) hydrocarbyl radical. Where cyclic or acyclic the alkyl group is preferably C<sub>1</sub> to C<sub>12</sub>, more preferably C<sub>1</sub> to C<sub>8</sub> (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, hexyl, heptyl, octyl). It will be appreciated therefore that the term "alkyl" as used herein includes alkyl (branched or unbranched), alkenyl (branched or unbranched), alkynyl (branched or unbranched), cycloalkyl, cycloalkenyl and cycloalkynyl. In a preferred embodiment, a cyclic alkyl group is preferably C<sub>3</sub> to C<sub>12</sub>, more preferably C<sub>5</sub> to C<sub>8</sub> and an acyclic alkyl group is preferably C<sub>1</sub> to C<sub>10</sub>, more preferably C<sub>1</sub> to C<sub>6</sub>, more preferably methyl, ethyl, propyl (n-propyl or isopropyl), butyl (n-butyl, isobutyl or tertiary-butyl) or pentyl (including n-pentyl and iso-pentyl), more preferably methyl.

20

Reference in the present specification to an "aryl" group means a mono or bicyclic aromatic group, such as phenyl or naphthyl.

25

The alkyl and aryl groups may be substituted or unsubstituted. In one embodiment, only the alkyl and aryl groups defined above as R<sub>1</sub> to R<sub>3</sub> may be substituted. Where substituted, there will generally be 1 to 3 substituents present, preferably 1 or 2 substituents. Substituents may include:

carbon containing groups such as

alkyl

aryl, arylalkyl (e.g. substituted and unsubstituted phenyl, substituted and unsubstituted benzyl);

5 halogen atoms and halogen containing groups such as

haloalkyl (e.g. trifluoromethyl);

oxygen containing groups such as

alcohols (e.g. hydroxy, hydroxyalkyl, (aryl)(hydroxy)alkyl),

ethers (e.g. alkoxy, alkoxyalkyl, aryloxyalkyl),

10 aldehydes (e.g. carboxaldehyde),

ketones (e.g. alkylcarbonyl, alkylcarbonylalkyl, arylcarbonyl, arylalkylcarbonyl, arylcarbonylalkyl),

acids (e.g. carboxy, carboxyalkyl),

acid derivatives such as esters

15 (e.g. alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl)

and amides

(e.g. aminocarbonyl, mono- or dialkylaminocarbonyl, aminocarbonylalkyl, mono- or dialkylaminocarbonylalkyl, arylaminocarbonyl);

20

nitrogen containing groups such as

amines (e.g. amino, mono- or dialkylamino, aminoalkyl, mono- or dialkylaminoalkyl),

azides,

25

nitriles (e.g. cyano, cyanoalkyl),

nitro;

sulphur containing groups such as

thiols, thioethers, sulfoxides and sulphones

(e.g. alkylthio, alkylsulfinyl, alkylsulfonyl, alkylthioalkyl, alkylsulfinylalkyl,

30

alkylsulfonylalkyl, arylthio, arylsulfinyl, arylsulfonyl, arylthioalkyl, arylsulfinylalkyl, arylsulfonylalkyl);

and heterocyclic groups containing one or more, preferably one, heteroatom,



5

10

(e.g. thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazoliny, pyrazolidinyl, tetrahydrofuranyl, pyranyl, pyronyl, pyridyl, pyrazinyl, pyridazinyl, piperidyl, piperazinyl, morpholinyl, thionaphthyl, benzofuranyl, isobenzofuryl, indolyl, oxyindolyl, isoindolyl, indazolyl, indoliny, 7-azaindolyl, isoindazolyl, benzopyranyl, coumarinyl, isocoumarinyl, quinolyl, isoquinolyl, naphthridinyl, cinnoliny, quinazoliny, pyridopyridyl, benzoxazinyl, quinoxadinyl, chromenyl, chromanyl, isochromanyl and carboliny).

Preferred substituents include alkyl, aryl, nitrile, halo, or an halogen-containing group such as trifluoromethyl.

As used herein, the term "alkoxy" means alkyl-O- and "alkoyl" means alkyl-CO-.

As used herein, the term "halogen" means a fluorine, chlorine, bromine or iodine radical, preferably a fluorine or chlorine radical.

The compounds of formula (I) may exist in a number of diastereomeric and/or enantiomeric forms. Unless otherwise stated, reference in the present specification to "a compound of formula (I)" is a reference to all stereoisomeric forms of the compound and includes a reference to the unseparated stereoisomers in a mixture, racemic or non-racemic, and to each stereoisomer in its pure form.

In a preferred embodiment of the present invention, a compound of formula (I) is the (*R*)-enantiomer of the compound of formula (I), substantially free of its (*S*)-enantiomer.

In the compounds of formula (I), preferably  $R^1$  is substituted or unsubstituted phenyl or naphthyl, more preferably  $R^1$  is a substituted phenyl or naphthyl, more preferably  $R^1$  is a phenyl or naphthyl having 1 to 3 substituents and most preferably  $R^1$  is a phenyl or naphthyl

having 1 or 2 substituents. Where  $R^1$  is a phenyl having 1 substituent, the phenyl group is preferably para- or meta-substituted. Where  $R^1$  is a phenyl having 2 substituents, the phenyl group is preferably substituted in the meta and para positions. The most preferred  $R^1$  groups are selected from 4-chlorophenyl, 4-fluorophenyl, 3-trifluoromethylphenyl, 3, 4-dichlorophenyl and 3, 4-difluorophenyl.

In the compounds of formula (I), preferably  $R^2$  is H or alkyl, more preferably  $R^2$  is H or acyclic hydrocarbyl, more preferably  $R^2$  is H or methyl and most preferably  $R^2$  is H.

- 10 In one embodiment of the present invention, in the compounds of formula (I),  $R^3$  is alkyl, preferably alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl or unsubstituted saturated cyclic or acyclic hydrocarbyl, and more preferably allyl or propargyl.

Particularly preferred compounds are as follows:

$R^1$	$R^2$	$R^3$
4-Cl-C <sub>6</sub> H <sub>4</sub>	H	Allyl
3,4-Cl <sub>2</sub> -C <sub>6</sub> H <sub>3</sub>	H	Allyl
3,4-F <sub>2</sub> -C <sub>6</sub> H <sub>3</sub>	H	Allyl
3-CF <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	H	Allyl
4-CF <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	H	Allyl
4-F-C <sub>6</sub> H <sub>4</sub>	H	Allyl
4-F-C <sub>6</sub> H <sub>4</sub>	H	Propargyl
4-Cl-C <sub>6</sub> H <sub>4</sub>	H	Propargyl
4-Cl-C <sub>6</sub> H <sub>4</sub>	4-Cl-C <sub>6</sub> H <sub>4</sub>	Allyl
4-Cl-C <sub>6</sub> H <sub>4</sub>	4-Cl-C <sub>6</sub> H <sub>4</sub>	2-Hydroxypropyl
3-Cl-C <sub>6</sub> H <sub>4</sub>	H	H
3-CF <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	H	H
3-CF <sub>3</sub> -C <sub>6</sub> H <sub>4</sub>	methyl	H

15

Of these, the preferred compounds are 3-(3,4-dichlorobenzyloxy)-N-(2-propenyl)azetidine-1-carboxamide, 3-(3-(trifluoromethyl)benzyloxy)-N-(2-propenyl)azetidine-1-carboxamide, 3-(4-(trifluoromethyl)benzyloxy)-N-(2-propenyl)azetidine-1-carboxamide, 3-(4-

fluorobenzyloxy)-N-(2-propenyl)azetidine-1-carboxamide, 3-(bis(4-chlorophenyl)methoxy)-N-(2-propenyl)azetidine-1-carboxamide, (R)-3-(bis(4-chlorophenyl)methoxy)-N-(2-hydroxypropyl)azetidine-1-carboxamide, 3-((3-chlorophenyl) methoxy)-azetidine-1-carboxamide and 3-(1-(3-trifluoromethylphenyl) ethyloxy)-azetidine-1-carboxamide.

5

According to a further aspect of the present invention there is provided a method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of the compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof.

10

According to a further aspect of the present invention there is provided a method of treatment of cerebral ischaemia, central nervous system injury or eye diseases comprising administration to a subject in need of such treatment an effective dose of the compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof.

15

The present invention may be employed in respect of a human or animal subject, more preferably a mammal, more preferably a human subject.

As used herein, the term "treatment" as used herein includes prophylactic treatment.

20

As used herein, the term "prodrug" means any pharmaceutically acceptable prodrug of the compound of formula (I). For example, the compound of formula (I) may be prepared in a prodrug form wherein a free -OH group is derivatised (for example, via an ester, amide or phosphate bond) with a suitable group (the group may contain, for example, an alkyl, aryl, phosphate, sugar, amine, glycol, sulfonate or acid function) which is suitably labile so as it

25

will be removed / cleaved (eg. by hydrolysis) to reveal the compound of formula (I) sometime after administration or when exposed to the desired biological environment.

As used herein, the term "pharmaceutically acceptable salt" means any pharmaceutically acceptable salt of the compound of formula (I). Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases including inorganic and organic acids and bases. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic,

30

lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like. Particularly preferred are hydrochloric, hydrobromic, phosphoric, sulfuric and methanesulfonic acids, and most particularly preferred is the methanesulfonate salt. Acceptable base salts include alkali metal (e.g. sodium, potassium), alkaline earth metal (e.g. calcium, magnesium) and aluminium salts.

As used herein, the term "substantially free of its (*S*)-enantiomer" means that the medicament or therapeutic composition comprising the compound of formula (I) used according to the present invention contains a greater proportion of the (*R*)-enantiomer of the compound of formula (I) in relation to the (*S*)-enantiomer of the compound of formula (I). In a preferred embodiment of the present invention the term "substantially free of its (*S*)-enantiomer", as used herein, means that the composition contains at least 90 % by weight of the (*R*)-enantiomer and 10 % by weight or less of the (*S*)-enantiomer. In a further preferred embodiment, the term "substantially free of its (*S*)-enantiomer" means that the composition contains at least 99 % by weight of the (*R*)-enantiomer and 1 % or less of the (*S*)-enantiomer. In another preferred embodiment, the term "substantially free of its (*S*)-enantiomer" means that the composition contains 100 % by weight of the (*R*)-enantiomer. The above percentages are based on the total amount of compound of formula (I) present in the medicament or therapeutic composition used according to the present invention.

The diseases, disorders and medical treatments/procedures to which the present invention is directed are:

25. Cerebral Ischaemia,  
including transient ischaemic attack, stroke (thrombotic stroke, ischaemic stroke, embolic stroke, haemorrhagic stroke, lacunar stroke), subarachnoid haemorrhage, cerebral vasospasm, neuroprotection for stroke, peri-natal asphyxia, drowning, carbon monoxide poisoning, cardiac arrest and subdural haematoma;
- 30 Central Nervous System Injury,  
including traumatic brain injury, neurosurgery (surgical trauma), neuroprotection for head injury, raised intracranial pressure, cerebral oedema, hydrocephalus and spinal cord injury;  
and

Eye Diseases,

including drug-induced optic neuritis, cataract, diabetic neuropathy, ischaemic retinopathy, retinal haemorrhage, retinitis pigmentosa, acute glaucoma, chronic glaucoma, macular degeneration, retinal artery occlusion and retinitis.


5

Additionally, the compound of formula (I) may also be used to potentiate the effects of other treatments, for example to potentiate the neuroprotective effects of brain derived nerve growth factor.

- 10 The invention is particularly directed to the treatment of cerebral ischaemia and central nervous system injury. The invention is also particularly directed to the treatment of post-asphyxial brain damage in new-born subjects.

The compound of formula (I) may be used in combination with one or more additional  
15 drugs useful in the treatment of the disorders mentioned above, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.

Compounds of formula (I) may be prepared according to the reaction scheme (where P is a  
20 nitrogen protecting group).  $R^1$ ,  $R^2$ , and  $R^3$  are as previously defined. The ether (IV) may be formed by reaction of the azetidinol (II) either with an arylalkanol (III,  $X = OH$ ) and diethylazo dicarboxylate and triphenyl phosphine or with an arylalkyl chloride, bromide, iodide, mesylate or tosylate (III,  $X = Cl, Br, I, \text{mesylate, tosylate}$ ) and a strong base such as sodium hydride. Formation of the azetidine (V) may be achieved by reaction of (IV) with a  
25 suitable nitrogen deprotection agent. For example, if P is a diphenylmethyl group, then deprotection may be carried out by treatment with 1-chloroethyl chloroformate followed by methanol. The urea (I) is formed by reaction of azetidine (V) with an N-alkylisocyanate or an N-alkylcarbonyl chloride and a base such as triethylamine or potassium carbonate. Alternatively, the urea may be prepared directly from the azetidine (IV) without isolation of  
30 an intermediate such as the secondary amine (V). For example, when P is a diphenylmethyl group, azetidine (IV) may be treated with phosgene followed by amine  $R^3NH_2$  to give urea (I) directly.

**Reaction Scheme**

The invention further provides a pharmaceutical composition comprising an effective amount of the compound of formula (I) in combination with a pharmaceutically acceptable carrier or excipient and a method of making such a composition comprising combining an effective amount of the compound of formula (I) with a pharmaceutically acceptable carrier or excipient.

To further increase efficacy, the composition may contain components such as dextrans or cyclodextrins or ether derivatives thereof, which aid stability and dispersion, and decrease metabolism of the active ingredient.

For compositions in which the pharmaceutically acceptable carrier comprises a cyclodextrin or an ether derivative thereof, the active ingredient is intimately mixed with an aqueous solution of the cyclodextrin or ether derivative thereof, with optional addition of further pharmaceutically acceptable ingredients before, during or after said mixing. The thus obtained solution is optionally lyophilized, and the lyophilized residue is optionally reconstituted with water.

In an embodiment of the present invention, the composition further comprises a buffer system, an isotonicizing agent and water.

Compounds of formula (I) may be administered in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use including transmucosal and transdermal use, for example a cream, ointment, gel, aqueous or oil solution or suspension, salve, patch or plaster; for nasal use, for example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository; for administration by inhalation, for example a finely divided powder or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oil solution or suspension. In general the above compositions may be prepared in a conventional manner using conventional excipients, using standard techniques well known to those skilled in the art of pharmacy. Preferably, the compound is administered orally.

For oral administration, the compounds of formula (I) will generally be provided in the form of tablets or capsules or as an aqueous solution or suspension.

15

Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.

25 Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.

For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of formula (I) will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Aqueous suspensions may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a

30

wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.

It will be appreciated that the dosage levels used may vary over quite a wide range depending upon the compound used, the severity of the symptoms exhibited by the patient and the patient's body weight.

The invention will now be described in detail with reference to the following pharmacological examples. It will be appreciated that the examples are intended to illustrate and not to limit the scope of the present invention.

## EXAMPLES

### Synthetic Examples

15

#### **Preparation of 1-(Diphenylmethyl)-3-azetidinol**

This compound was prepared according to the method of Anderson and Lok (*J. Org. Chem.*, 1972, 37, 3953, the disclosure of which is incorporated herein by reference), m.p. 111-112 °C (lit. m.p. 113 °C).

#### **Preparation of 3-(4-Chlorobenzyloxy)-1-(diphenylmethyl) azetidine (1)**

A solution of 1-diphenylmethyl-3-azetidinol (25 mmol) in DMF (100 mL) was added at 0 °C to a suspension of NaH (60% disp.in oil, 30 mmol) in DMF (50 mL). The reaction mixture was stirred at room temperature for 1h, then 4-chlorobenzylchloride (25 mmol) was added dropwise at 0 °C and the reaction mixture stirred at room temperature for 3 h. The reaction was quenched with water and extracted with ethyl acetate (3 x 50 mL), the extracts were washed with water and brine, dried (MgSO<sub>4</sub>) and concentrated *in vacuo*. The residue was purified by chromatography [SiO<sub>2</sub>; hexane-ethyl acetate (9:1)] to yield the product as a yellow oil (7.3 g, 80%). The material was used in the next step without further purification.

30 **Example 1. 3-(4-Chlorobenzyloxy)-N-(2-propenyl)azetidine-1-carboxamide (2)**



Phosgene solution (1.75-M in toluene, 24 mmol) was added at 0°C to a solution of compound (1) (20 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (40 mL). The reaction mixture was stirred at room temperature for 90 min, concentrated *in vacuo*, then redissolved in CH<sub>2</sub>Cl<sub>2</sub> (40 mL) and treated with allylamine (42 mmol) at 0°C. The reaction was stirred for 4 h at room temperature, then  
5 water (40 mL) was added and the layers were separated. The aqueous layer was extracted with further CH<sub>2</sub>Cl<sub>2</sub> (2 x 40 mL). The organic layers were washed with dilute HCl (20 mmol) and brine, dried (MgSO<sub>4</sub>) and concentrated *in vacuo*. The residue was triturated using diethyl ether to give the product (2) as a crystalline solid (3.5 g, 60%), m.p. 110-111 °C. Found: C, 59.84; H, 6.11; N, 9.98. C<sub>14</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>2</sub> requires: C, 59.89; H, 9.6.10; N, 9.97%.

10 **Preparation of 3-(3,4-Dichlorobenzoyloxy)-1-(diphenylmethyl) azetidine (3)**

This material was prepared from 1-diphenylmethyl-3-azetidinol (6.0 g) and alpha,3,4-trichlorotoluene using the procedure described for compound (1) (yield 92%).

**Example 2. 3-(3,4-Dichlorobenzoyloxy)-N-(2-propenyl)azetidine-1-carboxamide (4)**

This material was prepared from compound (3) (9.2 g) using the procedure described for  
15 compound (2) (yield 75%), m.p. 88-89 °C. Found: C, 53.43; H, 5.18; N, 8.85, C<sub>14</sub>H<sub>16</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub> requires C, 53.35; H, 5.12; N, 8.88%.

**Preparation of 3-(3-(Trifluoromethyl)benzyloxy)-1-(diphenylmethyl)azetidine (5)**

This material was prepared from 1-diphenylmethyl-3-azetidinol (5 g) and alpha'-bromo-alpha,alpha,alpha-trifluoro-*m*-xylene using the procedure described for compound (1) (yield  
20 91%).

**Example 3. 3-(3-(Trifluoromethyl)benzyloxy)-N-(2-propenyl)azetidine-1-carboxamide (6)**

This material was prepared from compound (5) (7.5 g) using the procedure described for  
25 compound (1) (yield 64%), m.p. 108°C. Found: C, 57.29; H, 5.44; N, 8.87, C<sub>15</sub>H<sub>17</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> requires C, 57.32; H, 5.45; N, 8.91%.

**Preparation of 3-(4-(Trifluoromethyl)benzyloxy)-1-(diphenylmethyl)azetidine (7)**

This material was prepared from 1-diphenylmethyl-3-azetidinol (6.0 g) and  $\alpha'$ -bromo- $\alpha,\alpha,\alpha$ -trifluoro-*p*-xylene using the procedure described for compound (1) (yield 77%).

**Example 4. 3-(4-(Trifluoromethyl)benzyloxy)-N-(2-propenyl)azetidine-1-carboxamide (8)**

- 5 This material was prepared from compound (7) (7.7 g) using the procedure described for compound (2) (yield 72%), m.p. 120 °C. Found: C, 57.27; H, 5.45; N, 8.86.  $C_{15}H_{17}F_3N_2O_2$  requires C, 57.32; H, 5.45, N, 8.91%.

**Preparation of 3-(4-Fluorobenzyloxy)-1-(diphenylmethyl) azetidine (9)**

10

This material was prepared from 1-diphenylmethyl-3-azetidinol (6.0 g) and 4-fluorobenzyl bromide using the procedure described for compound (1) (yield 83%).

**Example 5. 3-(4-Fluorobenzyloxy)-N-(2-propenyl)azetidine-1-carboxamide (10)**

15

This material was prepared from compound (9) using the procedure described for compound (2), m.p. 97-99 °C. Found: C, 63.57; H, 6.59; N, 10.66.  $C_{14}H_{17}ClN_2O_2$  requires C, 63.62; H, 6.48; N, 10.59.

**20 Preparation of 3-(bis-(4-chlorophenyl)methoxy)-1-diphenylmethyl)azetidine (11)**

- A solution of 4,4'-dichlorobenzhydrol (25 mmol), *p*-toluenesulfonic acid (18.4 mmol) and 1-(diphenylmethyl)-3-azetidinol (8.4 mmol) in benzene (100 mL) was heated under reflux in a Dean-Stark apparatus for 3h. The solution was cooled, washed with sodium hydrogen  
25 carbonate (saturated aqueous solution, 100 mL), dried ( $MgSO_4$ ) and concentrated *in vacuo*. The residue was purified by chromatography [ $SiO_2$ ; hexane-diethyl ether (5:1)] to yield the product (11) as a thick oil that crystallized on standing (2.4g, 62%).

**Example 6. 3-(Bis(4-chlorophenyl)methoxy)-N-(2-propenyl)azetidine-1-carboxamide**

30 (12)

This material was prepared from compound (11) using the procedure described for compound (2) (yield 17%) as a crystalline solid. Found: C, 56.38; H, 5.10; N, 6.51.  $C_{20}H_{20}Cl_2N_2O_2 \cdot 2H_2O$  requires: C, 56.21; H, 5.66; N, 6.56%.

5 **Example 7. Preparation of (R)-3-(Bis(4-chlorophenyl)methoxy)-N-(2-hydroxypropyl)azetidine-1-carboxamide (13)**

This material was prepared from compound (11) and (R)-(-)-1-amino-2-propanol using the procedure described for compound (2) (yield 57%) as a crystalline solid. Found: C, 58.74; H, 5.42; N, 6.84.  $C_{20}H_{22}Cl_2N_2O_3$  requires: C, 58.69; H, 5.42; N, 6.84%.

**Example 8. 3-(3-Trifluoromethyl)benzyloxy-N-azetidine-1-carboxamide (14)**

To a solution of 3-(3-trifluoromethyl)benzyloxy-1-(diphenylmethyl)azetidine (5) (5.3 mmol) in dichloromethane (15 mL) at 0°C, was added a solution of phosgene (1.75M in toluene, 6.4 mmol). The reaction mixture was stirred at room temperature for 2h, concentrated *in vacuo*, then redissolved in THF (15 mL) and treated with ammonium hydroxide (5 mL), added in one portion, at 0°C. The reaction was stirred vigorously for 15h at room temperature, then water (50 mL) and ethyl acetate (40 mL) were added and the layers were separated. The aqueous layer was extracted with ethyl acetate (2 x 40 mL), dried (MgSO<sub>4</sub>) and concentrated *in vacuo*. The residue was triturated using ethyl acetate (10 mL) to yield (14) as a solid (0.91 g, 63%), mp. 167 °C (ethyl acetate).

Found: C, 52.44; H, 4.72; N, 10.23.  $C_{14}H_{17}ClN_2O_2$  requires: C, 52.56; H, 4.78; N, 10.21.

25 **Preparation of 3-(1-(3-trifluoromethylphenyl)ethyloxy)-1-(diphenylmethyl)azetidine (15)**

To a solution of  $\alpha$ -methyl-3-trifluoromethylbenzyl alcohol (53 mmol), diisopropylethyl amine (105 mmol) in dichloromethane (150 mL) under nitrogen and cooled to 0 °C, was added methane sulfonyl chloride (63.1 mmol) dropwise over 10 min. The reaction was stirred for 15h. Water (200 mL) was added and the resulting mixture stirred for 10min, poured into potassium carbonate (10% wt/wt aqueous solution, 200 mL) and extracted with dichloromethane (3x150 mL). Combined organic extracts were washed with brine (50 mL) once and then dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated *in vacuo*. The residue was dissolved

in ethyl ether and washed through a pad of silica, eluting with more ether. The filtrate was concentrated *in vacuo*. This material was used directly, as shown below.

5 A solution of 1-diphenylmethyl-3-azetidinol (42 mmol) in dimethyl formamide (20 mL) was added via pipette, to a suspension of NaH (60% disp.in oil, 50 mmol) in dimethyl formamide (80 mL) at 0°C. The reaction mixture was stirred at room temperature for 15 min, the crude material from above (assumed 53 mmol) was added dropwise as a solution in dimethyl formamide (30 mL) at 0°C and the reaction mixture stirred at room temperature for 2 h. The reaction was poured into water (200 mL) and extracted with ethyl acetate (3 x 50 mL), the  
10 extracts were washed with water (200 mL) and brine (50 mL), dried (MgSO<sub>4</sub>) and concentrated *in vacuo*. The residue was purified by chromatography (SiO<sub>2</sub>; hexane/ethyl acetate 9/1) to yield 3-(1-(3-trifluoromethylphenyl)ethoxy)-1-(diphenylmethyl)azetidine (15) as a yellow oil (11.2g, yield 65%). The material was used in the next step without further purification.

15

**Example 9. 3-(1-(3-Trifluoromethylphenyl)ethoxy)-azetidine-1-carboxamide (16)**

This material was prepared from compound (15) using the procedure described for compound (14) (yield 62%) as a crystalline solid, mp. 130.5-131.5°C (diisopropyl ether).









20 Found: C, 54.24; H, 5.26; N, 9.69. C<sub>14</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>2</sub> requires: C, 54.17; H, 5.24.; N, 9.71.









The individual enantiomers of Example 9 are prepared using the same overall synthetic method as described for compound 16, but using the chiral alcohols. The *R*-enantiomer of Example 9 was prepared from the appropriate chiral 1-(3-trifluoromethyl)phenyl ethyl  
25 alcohol. The chiral alcohols may be prepared from 3'-trifluoromethyl-acetophenone by stereoselective reduction, for example using borane and a suitable chiral auxiliary or chiral catalyst (see Corey, EJ; Bakshi, RK; Shibata S. *J. Amer. Chem. Soc.*, **1987**, *109*, 5551-5553 or Pickard, ST and Smith, HE. *J. Amer. Chem. Soc.*, **1990**, *112*, 5741-5747).









**Examples 10 to 43 – See Table 1**

These products were prepared using the procedure described for compound (2).









Table 1



Exempleno	Compound No.	Structure	Formula	MWt	mp	Cfound	Hfound	Nfound	Cexp	Hexp	Nexp	Note
10	17		C <sub>15</sub> H <sub>17</sub> N <sub>3</sub> O <sub>2</sub>	271.32	95-96	66.69	6.29	15.32	66.40	6.32	15.48	
11	18		C <sub>20</sub> H <sub>22</sub> N <sub>2</sub> O <sub>2</sub>	322.41	160.0	74.52	6.87	8.61	74.51	6.88	8.68	
12	19		C <sub>18</sub> H <sub>20</sub> N <sub>2</sub> O <sub>2</sub>	296.37	141-142	72.96	6.77	9.65	72.95	6.80	9.45	
13	20		C <sub>14</sub> H <sub>18</sub> C <sub>2</sub> N <sub>2</sub> O <sub>2</sub>	317.22	89-90	53.00	5.74	8.73	53.01	5.72	8.83	
14	21		C <sub>14</sub> H <sub>17</sub> C <sub>2</sub> N <sub>2</sub> O <sub>2</sub>	280.76	67-68	59.94	6.12	9.95	59.89	6.10	9.97	
15	22		C <sub>14</sub> H <sub>17</sub> F <sub>2</sub> N <sub>2</sub> O <sub>2</sub>	264.30	59-60	63.55	6.55	10.59	63.62	6.48	10.59	
16	23		C <sub>15</sub> H <sub>19</sub> F <sub>3</sub> N <sub>2</sub> O <sub>2</sub>	316.33	128-129	56.92	6.09	8.83	56.96	6.05	8.85	
17	24		C <sub>15</sub> H <sub>19</sub> F <sub>3</sub> N <sub>2</sub> O <sub>2</sub>	316.33	62-63	56.89	6.21	8.82	56.96	6.05	8.85	

Exempleno	Compound No.	Structure	Formula	MWt	mp	Cfound	Hfound	Nfound	Cexp	Hexp	Nexp	Note
18	25		C <sub>15</sub> H <sub>19</sub> F <sub>3</sub> N <sub>2</sub> O <sub>3</sub>	332.33	67-68	54.25	5.81	8.42	54.21	5.76	8.43	
19	26		C <sub>15</sub> H <sub>19</sub> F <sub>3</sub> N <sub>2</sub> O <sub>3</sub>	332.33	67-68	54.21	5.87	8.41	54.21	5.76	8.43	
20	27		C <sub>15</sub> H <sub>19</sub> F <sub>3</sub> N <sub>2</sub> O <sub>3</sub>	332.33	97-98	54.09	5.76	8.39	54.21	5.76	8.43	
21	28		C <sub>15</sub> H <sub>19</sub> F <sub>3</sub> N <sub>2</sub> O <sub>3</sub>	332.33	97-98	54.39	5.82	8.44	54.21	5.76	8.43	
22	29		C <sub>14</sub> H <sub>18</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>3</sub>	333.22	88-89	50.46	5.34	8.39	50.46	5.44	8.40	
23	30		C <sub>14</sub> H <sub>18</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>3</sub>	333.22	88-89	50.49	5.36	8.61	50.46	5.44	8.40	
24	31		C <sub>14</sub> H <sub>19</sub> ClN <sub>2</sub> O <sub>3</sub>	298.77	85-86	56.27	6.40	9.35	56.28	6.41	9.37	
25	32		C <sub>15</sub> H <sub>15</sub> F <sub>3</sub> N <sub>2</sub> O <sub>2</sub>	312.29	90-91	57.73	4.94	8.91	57.69	4.84	8.97	

Exempleno	Compound No.	Structure	Formula	MWt	mp	Cfound	Hfound	Nfound	Cexp	Hexp	Nexp	Note
26	33		C <sub>14</sub> H <sub>18</sub> N <sub>2</sub> O <sub>2</sub>	246.31	76-77	68.29	7.35	11.37	68.27	7.37	11.37	
27	34		C <sub>14</sub> H <sub>19</sub> F <sub>3</sub> N <sub>2</sub> O <sub>3</sub>	282.32	73-74	59.49	6.87	9.93	59.56	6.78	9.92	
28	35		C <sub>15</sub> H <sub>17</sub> F <sub>3</sub> N <sub>2</sub> O <sub>2</sub>	314.31	63.0	57.34	5.47	8.92	57.32	5.45	8.91	
29	36		C <sub>14</sub> H <sub>16</sub> F <sub>2</sub> N <sub>2</sub> O <sub>2</sub>	282.29	75.0	59.59	5.72	9.88	59.57	5.71	9.92	
30	37		C <sub>14</sub> H <sub>16</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>2</sub>	315.20	100.0	53.15	4.99	8.86	53.35	5.12	8.88	
31	38		C <sub>14</sub> H <sub>16</sub> F <sub>2</sub> N <sub>2</sub> O <sub>2</sub>	282.29	79.0	59.55	5.73	9.90	59.57	5.71	9.92	
32	39		C <sub>16</sub> H <sub>19</sub> F <sub>3</sub> N <sub>2</sub> O <sub>2</sub>	328.34	oil							a
33	40		C <sub>14</sub> H <sub>16</sub> F <sub>2</sub> N <sub>2</sub> O <sub>2</sub>	282.29	82.5-85	59.72	5.69	9.98	59.57	5.71	9.92	



Exempleno	Compound No.	Structure	Formula	MWt	mp	Clound	Hfound	Nfound	Cexp	Hexp	Nexp	Note
34	41		C <sub>14</sub> H <sub>16</sub> F <sub>2</sub> N <sub>2</sub> O <sub>2</sub>	282.29	91-92.5	59.58	5.62	9.94	59.51	5.71	9.92	
35	42		C <sub>18</sub> H <sub>16</sub> F <sub>6</sub> N <sub>2</sub> O <sub>2</sub>	382.31	80.5-81.5	50.38	4.25	7.32	50.27	4.22	7.32	
36	43		C <sub>14</sub> H <sub>15</sub> ClN <sub>2</sub> O <sub>2</sub>	298.77	76-78	56.94	6.34	10.25	56.28	6.41	9.37	
37	44		C <sub>14</sub> H <sub>15</sub> ClN <sub>2</sub> O <sub>2</sub>	278.74	123-124	60.88	5.58	9.91	60.33	5.42	10.05	
38	45		C <sub>18</sub> H <sub>16</sub> F <sub>2</sub> N <sub>2</sub> O <sub>2</sub>	300.40	94-96	71.89	8.08	9.28	71.97	8.05	9.32	
39	46		C <sub>18</sub> H <sub>16</sub> F <sub>2</sub> N <sub>2</sub> O <sub>2</sub>	320.44	oil							b
40	47		C <sub>14</sub> H <sub>19</sub> F <sub>2</sub> N <sub>2</sub> O <sub>3</sub>	282.32	72-73	59.32	6.84	9.81	59.56	6.78	9.92	
41	48		C <sub>18</sub> H <sub>26</sub> N <sub>2</sub> O <sub>2</sub>	302.42	79-80	71.25	8.79	9.36	71.49	8.67	9.26	

Exempleno	Compound No.	Structure	Formula	MWt	mp	Clound	Hfound	Nfound	Cexp	Hexp	Nexp	Note
42	49		C <sub>14</sub> H <sub>17</sub> F <sub>3</sub> N <sub>2</sub> O <sub>2</sub>	302.30	110.5- 112	55.64	5.77	9.26	55.63	5.67	9.26	
43	50		C <sub>14</sub> H <sub>15</sub> FN <sub>2</sub> O <sub>2</sub>	262.29	94-96	64.29	5.47	10.70	64.11	5.76	10.68	

**Footnotes for Table 1**

Footnote a: IR: 3296, 2980, 2943, 2877, 1638, 1545, 1400, 1377, 1330, 1203, 1166, 1127, 1073, 706  $\text{cm}^{-1}$ .

- 5 Footnote b: IR 3319, 2963, 2872, 1634, 1549, 1469, 1403, 1327, 1269, 1184, 1130, 1083, 818  $\text{cm}^{-1}$ .

**Example 44. 3-((3-chlorophenyl)methoxy)-azetidine-1-carboxamide (51)**

- 10 This material was prepared from compound (1) using the procedure described for compound (14) (yield 87%) as a crystalline solid, m.p. 163-165.5°C (diisopropyl ether).

Found: C, 55.49; H, 5.45; N, 11.40.  $\text{C}_{11}\text{H}_{13}\text{ClN}_2\text{O}_2$  requires: C, 54.89; H, 5.44.; N, 11.63.

**Testing Procedures**

15

**Rat transient middle cerebral artery occlusion (MCAo) ischaemia model**

- This model of middle cerebral artery occlusion used relies on an intraluminal filament technique in the rat (Zhao Q. *et al.*, *Acta Physiol. Scand.* 1994, 152, 349-350). Male Lister Hooded rats were used in these experiments and were divided into three groups (Group 1: vehicle; Group 2: chlomethiazole (CMZ); Group 3: compound of formula (I)). The sample size in each was 11 to 15. The animal was anaesthetised and the carotid artery exposed. A heat rounded dermalon suture (3/0) of a specified diameter was introduced into the ligated carotid artery, past the bifurcations of the external and common carotid, the internal carotid and the pterygopalatine artery, into the intracranial circulation. The filament then lodged in the narrow proximal anterior carotid occluding the middle cerebral artery. After 90 min. of middle cerebral artery occlusion, the filament was removed, allowing re-circulation.

- 22.5 h following reperfusion, the animal was perfused *via* the transaortic route, using 200 ml of a 4 percent solution of tetrazolium chloride warmed to 37° C. Following perfusion, the brain was removed and immersion fixed in 10 percent formalin/saline for at least 48 h. Following fixation, the brain was sliced into 0.5 mm sections on a vibroslice. Using this technique, viable tissue was stained dark red and infarcted tissue remains unstained. The

area of infarction on each section was measured, and the total volume of infarction in the hemisphere, cortex and striatum computed, using the Kontron image analysis system.

#### **Mouse permanent middle cerebral artery occlusion ischaemia model**

- 5 Adult male C57Bl mice (20-25 g, n = 10 per group) were administered a compound of formula (I) (10 mg/kg) or vehicle (60% PEG400 in water) i.p. 30 minutes prior to middle cerebral artery (MCA) occlusion. Under halothane anaesthesia (1.5% halothane in nitrous oxide: oxygen (70:30)), a small craniectomy was made to expose the left MCA. The distal portion of the MCA was occluded by electrocoagulation. The incision site was sutured and
- 10 anaesthetics withdrawn. 24 h following MCA occlusion, the mouse was euthanised, the brain removed and immersed in 4% tetrazolium chloride to visualise the area of infarction (Backhaus C. *et al.*, *J. Pharm Methods* **1992**, 27, 27-32). Brains were then stored in 10% formalin/saline. The area of infarction as visible on the cortical surface was then computed using a PC digital imaging system (KS300, Imaging Associates, UK). Data generated is
- 15 absolute area of infarction in mm<sup>2</sup> for each animal. Mean infarct areas were compared by unpaired t-tests with significance taken at  $p < 0.05$ .

The experimental results are displayed in Figures 1 and 2 which show the effects of (i) vehicle; and (ii) a compound of formula (I) on infarction after permanent middle cerebral

20 artery occlusion.


Figure 1 shows that the *R*-enantiomer of compound 16 when administered 30 min. prior to occlusion exhibits significant neuroprotection at a dose of 60 mg/kg i.p. in the mouse permanent MCAo model.

25

Figure 2 shows that compound 51 when administered concurrently with occlusion exhibits significant neuroprotection at a dose of 100 mg/kg i.p. in the mouse permanent MCAo model.

**CLAIMS**

1. Use of a compound of formula (I)



(I)

wherein:

R<sup>1</sup> is aryl;

R<sup>2</sup> is H, alkyl or aryl; and

R<sup>3</sup> is hydrogen or alkyl;

or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for neuroprotection in a subject or for the treatment of cerebral ischaemia, central nervous system injury or eye diseases.

2. A use according to claim 1 wherein R<sup>1</sup> is a substituted or unsubstituted phenyl or naphthyl.

3. A use according to claim 1 or 2 wherein R<sup>1</sup> has 1, 2 or 3 substituent groups.

4. A use according to claim 1, 2 or 3 wherein R<sup>1</sup> is chlorophenyl, fluorophenyl, (trifluoromethyl)phenyl, 3, 4-dichlorophenyl or 3, 4-difluorophenyl.

5. A use according to claim 1, 2, 3 or 4 wherein R<sup>2</sup> is hydrogen or methyl.

6. A use according to any one of claims 1 to 5 wherein R<sup>3</sup> is alkyl.

7. A use according to any one of claims 1 to 5 wherein R<sup>3</sup> is alkenyl, alkynyl, hydroxyalkyl or alkoxyalkyl.

8. A use according to any preceding claim wherein R<sup>3</sup> is allyl or propargyl.

9. A use according to any one of claims 1 to 5 wherein R<sup>3</sup> is unsubstituted saturated cyclic or acyclic hydrocarbonyl.

5 10. A use according to claim 1 wherein the compound is selected from:

3-(4-chlorobenzyloxy)-N-(2-propenyl)azetidine-1-carboxamide,

3-(3,4-dichlorobenzyloxy)-N-(2-propenyl)azetidine-1-carboxamide,

3-(3-(trifluoromethyl)benzyloxy)-N-(2-propenyl)azetidine-1-carboxamide,

3-(4-(trifluoromethyl)benzyloxy)-N-(2-propenyl)azetidine-1-carboxamide,

10 3-(4-fluorobenzyloxy)-N-(2-propenyl)azetidine-1-carboxamide,

3-(bis(4-chlorophenyl)methoxy)-N-(2-propenyl)azetidine-1-carboxamide,

(R)-3-(bis(4-chlorophenyl)methoxy)-N-(2-hydroxypropyl)azetidine-1-carboxamide,

3-((3-chlorophenyl) methoxy)-azetidine-1-carboxamide, and

3-(1-(3-trifluoromethylphenyl)ethyloxy)-azetidine-1-carboxamide.

15

11. A use according to any preceding claim wherein said medicament comprises a pharmaceutically acceptable carrier and as active ingredient an effective amount of a compound of formula (I).

20 12. A use according to claim 11 wherein said carrier comprises a cyclodextrin or an ether derivative thereof.


13. A use according to any preceding claim wherein the medicament further comprises a buffer system, an isotonicizing agent and water.

25


14. Use according to any of preceding claim wherein the compound of formula (I) is in combination with one or more additional drugs useful in neuroprotection or in the treatment of cerebral ischaemia, central nervous system injury or eye diseases, the components being in the same formulation or in separate formulations for administration

30 simultaneously or sequentially.

15. A method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) as defined in any of claims 1 to 10, or a pharmaceutically acceptable salt or prodrug thereof.
- 5 16. A method of treatment of cerebral ischaemia, central nervous system injury or eye diseases comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) as defined in any of claims 1 to 10, or a pharmaceutically acceptable salt or prodrug thereof.
- 10 17. A method according to claim 15 or 16 wherein the compound of formula (I) is administered in the form as set out in any of claims 11, 12, 13 or 14.

**Figure 1**

5

**Figure 2**



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/02841

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/397 A61P39/00 A61P25/00 A61P25/28 A61P27/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EMBASE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 505 907 A (G.J. WRIGHT ET AL.) 19 March 1985 (1985-03-19) the whole document	1-17
A	US 5 095 014 A (C.R. TAYLOR ET AL.) 10 March 1992 (1992-03-10) the whole document	1-17
A	US 4 226 861 A (A.D. CALE) 7 October 1980 (1980-10-07) the whole document	1-17
A	CH 645 352 A (A.H. ROBINS COMPANY) 28 September 1984 (1984-09-28) the whole document	1-17
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

9 March 2001

Date of mailing of the international search report

15/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gac, G

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/02841

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 102 194 A (A.H. ROBINS COMPANY) 7 March 1984 (1984-03-07) the whole document ---	1-17
A	US 5 183 903 A (W.J. WELSTEAD) 2 February 1993 (1993-02-02) the whole document ---	1-17
A	EP 0 194 112 A (A.H. ROBINS COMPANY) 10 September 1986 (1986-09-10) the whole document ---	1-17
A	ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 192th ANNUAL MEET., 7-12 SEPTEMBER 1986, p.4-MEDI XP000987264 abstract ---	1-17
E	WO 01 07043 A (VERNALIS RESEARCH LIMITED) 1 February 2001 (2001-02-01)  the whole document ---	1-5,7, 11-13, 15-17
P,A	WO 99 37612 A (CEREBRUS LIMITED) 29 July 1999 (1999-07-29) cited in the application the whole document ---	1-17
P,A	WO 99 37614 A (CEREBRUS LIMITED) 29 July 1999 (1999-07-29) cited in the application the whole document -----	1-17

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/GB 00/02841

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4505907 A	19-03-1985	AT 23329 T	15-11-1986
		AU 553472 B	17-07-1986
		AU 1459883 A	08-03-1984
		CA 1185983 A	23-04-1985
		CS 8306141 A	13-06-1985
		DE 3367385 D	11-12-1986
		DK 398783 A,C	03-03-1984
		EG 16473 A	30-12-1990
		EP 0102740 A	14-03-1984
		ES 523194 D	16-04-1985
		ES 8504697 A	16-07-1985
		ES 537668 D	16-09-1985
		ES 8600234 A	01-01-1986
		FI 833126 A,B,	03-03-1984
		GR 79337 A	22-10-1984
		HK 47587 A	26-06-1987
		HU 189740 B	28-07-1986
		IE 55770 B	16-01-1991
		IN 161940 A	27-02-1988
		IN 161222 A	24-10-1987
		JP 1772175 C	14-07-1993
		JP 4052264 B	21-08-1992
		JP 60001161 A	07-01-1985
		KE 3696 A	13-03-1987
		KR 9005131 B	20-07-1990
		NO 833135 A,B,	05-03-1984
		NZ 205448 A	30-08-1985
		PH 20572 A	18-02-1987
		PL 243555 A	27-08-1984
		PT 77281 A,B	01-10-1983
		YU 170483 A	30-04-1986
		ZA 8304410 A	28-03-1984
US 5095014 A	10-03-1992	AT 113034 T	15-11-1994
		AU 9084091 A	08-07-1992
		CA 2097835 A	08-06-1992
		DE 69104731 D	24-11-1994
		DE 69104731 T	16-02-1995
		DK 560905 T	18-04-1995
		EP 0560905 A	22-09-1993
		ES 2061336 T	01-12-1994
		IE 914169 A	17-06-1992
		JP 6503324 T	14-04-1994
		MX 9102326 A,B	01-06-1992
		NZ 240882 A	25-02-1993
		PT 99646 A,B	30-10-1992
		WO 9210474 A	25-06-1992
US 4226861 A	07-10-1980	AU 571258 B	14-04-1988
		CA 1161853 A	07-02-1984
		CH 645352 A	28-09-1984
		DE 3037770 A	19-05-1982
		FR 2491467 A	09-04-1982
		GB 2084993 A,B	21-04-1982
		JP 1003185 B	19-01-1989
		JP 1524428 C	12-10-1989
		JP 57064665 A	19-04-1982
		NL 8005514 A,B,	03-05-1982

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 00/02841

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4226861 A		AU 3225284 A BE 885549 A CA 1169870 A GB 2085435 A,B	26-04-1985 02-02-1981 26-06-1984 28-04-1982
CH 645352 A	28-09-1984	AU 571258 B CA 1161853 A DE 3037770 A FR 2491467 A GB 2084993 A,B JP 1003185 B JP 1524428 C JP 57064665 A NL 8005514 A,B, US 4226861 A AU 3225284 A BE 885549 A CA 1169870 A GB 2085435 A,B	14-04-1988 07-02-1984 19-05-1982 09-04-1982 21-04-1982 19-01-1989 12-10-1989 19-04-1982 03-05-1982 07-10-1980 26-04-1985 02-02-1981 26-06-1984 28-04-1982
EP 102194 A	07-03-1984	AT 23037 T AU 553528 B AU 1459783 A CA 1173841 A CS 236796 B DE 3367089 D DK 376183 A,B, EG 16472 A ES 523193 D ES 8500225 A FI 832956 A,B, GR 79634 A HK 47487 A HU 190608 B IE 55769 B IL 68699 A IN 157045 A JP 1928821 C JP 6043388 B JP 59080657 A KE 3691 A KR 9001210 B MX 9203639 A NO 832971 A,B, NZ 205317 A PH 19595 A PL 243255 A PT 77217 A,B US 4571393 A YU 158683 A ZA 8304371 A	15-11-1986 17-07-1986 23-02-1984 04-09-1984 15-05-1985 27-11-1986 20-02-1984 30-03-1987 01-10-1984 01-01-1985 20-02-1984 31-10-1984 26-06-1987 29-09-1986 16-01-1991 31-08-1986 04-01-1986 12-05-1995 08-06-1994 10-05-1984 06-03-1987 28-02-1990 01-07-1992 20-02-1984 30-08-1985 26-05-1986 27-08-1984 01-09-1983 18-02-1986 31-12-1985 28-03-1984
US 5183903 A	02-02-1993	CA 2083440 A EP 0544475 A JP 5221963 A	27-05-1993 02-06-1993 31-08-1993
EP 194112 A	10-09-1986	AT 52915 T AU 599585 B	15-06-1990 26-07-1990

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/02841

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 194112 A		AU 5388786 A	04-09-1986
		CY 1724 A	06-05-1994
		DE 3671369 D	28-06-1990
		DK 90086 A	29-08-1986
		FI 860847 A,B,	29-08-1986
		GR 860549 A	24-06-1986
		HK 83893 A	20-08-1993
		IE 58943 B	01-12-1993
		JP 1965813 C	25-03-1995
		JP 6099306 B	07-12-1994
		JP 61210031 A	18-09-1986
		NZ 215313 A	26-02-1990
		PH 25455 A	01-07-1991
		PT 82117 A,B	01-03-1986
		SG 50893 G	09-07-1993
		US 4956359 A	11-09-1990
		ZA 8601210 A	28-10-1987
		AU 599312 B	19-07-1990
		AU 5388886 A	04-09-1986
		CA 1294274 A	14-01-1992
		DK 36893 A	29-03-1993
		DK 90186 A	29-08-1986
		ES 552472 D	01-05-1987
		ES 8802300 A	16-07-1988
		GR 860531 A	24-06-1986
		IL 77995 A	30-06-1989
		IN 162808 A	09-07-1988
		JP 1965814 C	25-08-1995
		JP 6099386 B	07-12-1994
		JP 61205254 A	11-09-1986
		NZ 215312 A	26-02-1990
		PH 25525 A	24-07-1991
		PT 82118 A,B	01-03-1986
		US 5183902 A	02-02-1993
		US 5151418 A	29-09-1992
		US 5068231 A	26-11-1991
		ZA 8601215 A	29-10-1986
WO 0107043 A	01-02-2001	NONE	
WO 9937612 A	29-07-1999	AU 2287499 A	09-08-1999
		EP 1049672 A	08-11-2000
WO 9937614 A	29-07-1999	AU 2178199 A	09-08-1999
		EP 1049671 A	08-11-2000

## PATENT COOPERATION TREATY

PCT

REC'D 16 OCT 2001

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

14

Applicant's or agent's file reference P022293WO	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GB00/02841	International filing date (day/month/year) 21/07/2000	Priority date (day/month/year) 23/07/1999
International Patent Classification (IPC) or national classification and IPC A61K31/00		
Applicant VERNALIS RESEARCH LIMITED et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 6 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  22/02/2001	Date of completion of this report  12.10.2001
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Brück, M  Telephone No. +49 89 2399 8735



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/02841

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-26 as originally filed

**Claims, No.:**

1-17 as originally filed

**Drawings, sheets:**

1/1 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB00/02841

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 15-17.

because:

☒ the said international application, or the said claims Nos. 15-17 relate to the following subject matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)

Yes: Claims 1-17



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/02841

	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-17
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-14
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

## VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

Section III

1. Claims 15-17 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Section V

1. Novelty and Inventive step

Cf. Section VIII,1 for the conditions under which the following opinion is valid:

The claims are considered to be novel and inventive because the claimed compound I has not been disclosed or suggested for the claimed conditions.

The prior art only mentions the compound as antidepressant, anti-convulsant, anti-epileptic etc.

2. Industrial applicability

For the assessment of the present claims 15-17 on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims.

The EPO does not, for example, recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Section VIII

1. The above opinion has been established by interpreting the conditions claimed

such as "neuroprotection", "cerebral ischaemia", "central nervous system injury" and "eye disease" in the light of the specification on page 10-11.

However, to fulfill Article 6 PCT it is necessary to unambiguously define these general conditions--according to the specification-- **also in the claims.**

2. Claim 14 refers to drugs which are characterized only by results to be achieved, viz., "useful in neuroprotection, in the treatment of cerebral ischaemia, central nervous system injury or eye disease" which renders the claim unclear (cf. PCT Preliminary Examination Guidelines, C-III, 4.7).

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>P022293W0</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/GB 00/02841</b>	International filing date (day/month/year) <b>21/07/2000</b>	(Earliest) Priority Date (day/month/year) <b>23/07/1999</b>
Applicant <b>VERNALIS RESEARCH LIMITED et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

**AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES**

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/02841

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/397 A61P39/00 A61P25/00 A61P25/28 A61P27/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EMBASE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 505 907 A (G.J. WRIGHT ET AL.) 19 March 1985 (1985-03-19) the whole document ---	1-17
A	US 5 095 014 A (C.R. TAYLOR ET AL.) 10 March 1992 (1992-03-10) the whole document ---	1-17
A	US 4 226 861 A (A.D. CALE) 7 October 1980 (1980-10-07) the whole document ---	1-17
A	CH 645 352 A (A.H. ROBINS COMPANY) 28 September 1984 (1984-09-28) the whole document ---	1-17
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

9 March 2001

Date of mailing of the international search report

15/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gac, G

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/02841

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 102 194 A (A.H. ROBINS COMPANY) 7 March 1984 (1984-03-07) the whole document ----	1-17
A	US 5 183 903 A (W.J. WELSTEAD) 2 February 1993 (1993-02-02) the whole document ----	1-17
A	EP 0 194 112 A (A.H. ROBINS COMPANY) 10 September 1986 (1986-09-10) the whole document ----	1-17
A	ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 192th ANNUAL MEET., 7-12 SEPTEMBER 1986, p.4-MEDI XP000987264 abstract ----	1-17
E	WO 01 07043 A (VERNALIS RESEARCH LIMITED) 1 February 2001 (2001-02-01)  the whole document ----	1-5,7, 11-13, 15-17
P,A	WO 99 37612 A (CEREBRUS LIMITED) 29 July 1999 (1999-07-29) cited in the application the whole document ----	1-17
P,A	WO 99 37614 A (CEREBRUS LIMITED) 29 July 1999 (1999-07-29) cited in the application the whole document -----	1-17

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/02841

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4505907	A	19-03-1985	AT 23329 T	15-11-1986
			AU 553472 B	17-07-1986
			AU 1459883 A	08-03-1984
			CA 1185983 A	23-04-1985
			CS 8306141 A	13-06-1985
			DE 3367385 D	11-12-1986
			DK 398783 A,C	03-03-1984
			EG 16473 A	30-12-1990
			EP 0102740 A	14-03-1984
			ES 523194 D	16-04-1985
			ES 8504697 A	16-07-1985
			ES 537668 D	16-09-1985
			ES 8600234 A	01-01-1986
			FI 833126 A,B,	03-03-1984
			GR 79337 A	22-10-1984
			HK 47587 A	26-06-1987
			HU 189740 B	28-07-1986
			IE 55770 B	16-01-1991
			IN 161940 A	27-02-1988
			IN 161222 A	24-10-1987
			JP 1772175 C	14-07-1993
			JP 4052264 B	21-08-1992
			JP 60001161 A	07-01-1985
			KE 3696 A	13-03-1987
			KR 9005131 B	20-07-1990
			NO 833135 A,B,	05-03-1984
			NZ 205448 A	30-08-1985
			PH 20572 A	18-02-1987
			PL 243555 A	27-08-1984
			PT 77281 A,B	01-10-1983
			YU 170483 A	30-04-1986
			ZA 8304410 A	28-03-1984
US 5095014	A	10-03-1992	AT 113034 T	15-11-1994
			AU 9084091 A	08-07-1992
			CA 2097835 A	08-06-1992
			DE 69104731 D	24-11-1994
			DE 69104731 T	16-02-1995
			DK 560905 T	18-04-1995
			EP 0560905 A	22-09-1993
			ES 2061336 T	01-12-1994
			IE 914169 A	17-06-1992
			JP 6503324 T	14-04-1994
			MX 9102326 A,B	01-06-1992
			NZ 240882 A	25-02-1993
			PT 99646 A,B	30-10-1992
			WO 9210474 A	25-06-1992
US 4211111	A	07-10-1980	AU 571258 B	14-04-1988
			CA 1161853 A	07-02-1984
			CH 645352 A	28-09-1984
			DE 3037770 A	19-05-1982
			FR 2491467 A	09-04-1982
			GB 2084993 A,B	21-04-1982
			JP 1003185 B	19-01-1989
			JP 1524428 C	12-10-1989
			JP 57064665 A	19-04-1982
			NL 8005514 A,B,	03-05-1982

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/02841

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4226861	A		AU 3225284 A	26-04-1985
			BE 885549 A	02-02-1981
			CA 1169870 A	26-06-1984
			GB 2085435 A, B	28-04-1982
CH 645352	A	28-09-1984	AU 571258 B	14-04-1988
			CA 1161853 A	07-02-1984
			DE 3037770 A	19-05-1982
			FR 2491467 A	09-04-1982
			GB 2084993 A, B	21-04-1982
			JP 1003185 B	19-01-1989
			JP 1524428 C	12-10-1989
			JP 57064665 A	19-04-1982
			NL 8005514 A, B,	03-05-1982
			US 4226861 A	07-10-1980
			AU 3225284 A	26-04-1985
			BE 885549 A	02-02-1981
			CA 1169870 A	26-06-1984
			GB 2085435 A, B	28-04-1982
EP 102194	A	07-03-1984	AT 23037 T	15-11-1986
			AU 553528 B	17-07-1986
			AU 1459783 A	23-02-1984
			CA 1173841 A	04-09-1984
			CS 236796 B	15-05-1985
			DE 3367089 D	27-11-1986
			DK 376183 A, B,	20-02-1984
			EG 16472 A	30-03-1987
			ES 523193 D	01-10-1984
			ES 8500225 A	01-01-1985
			FI 832956 A, B,	20-02-1984
			GR 79634 A	31-10-1984
			HK 47487 A	26-06-1987
			HU 190608 B	29-09-1986
			IE 55769 B	16-01-1991
			IL 68699 A	31-08-1986
			IN 157045 A	04-01-1986
			JP 1928821 C	12-05-1995
			JP 6043388 B	08-06-1994
			JP 59080657 A	10-05-1984
			KE 3691 A	06-03-1987
			KR 9001210 B	28-02-1990
			MX 9203639 A	01-07-1992
			NO 832971 A, B,	20-02-1984
			NZ 205317 A	30-08-1985
			PH 19595 A	26-05-1986
			PL 243255 A	27-08-1984
			PT 77217 A, B	01-09-1983
			US 4571393 A	18-02-1986
			YU 158683 A	31-12-1985
			ZA 8304371 A	28-03-1984
US 5183903	A	02-02-1993	CA 2083440 A	27-05-1993
			EP 0544475 A	02-06-1993
			JP 5221963 A	31-08-1993
EP 194112	A	10-09-1986	AT 52915 T	15-06-1990
			AU 599585 B	26-07-1990



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/02841

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 194112	A		AU 5388786 A	04-09-1986
			CY 1724 A	06-05-1994
			DE 3671369 D	28-06-1990
			DK 90086 A	29-08-1986
			FI 860847 A,B,	29-08-1986
			GR 860549 A	24-06-1986
			HK 83893 A	20-08-1993
			IE 58943 B	01-12-1993
			JP 1965813 C	25-08-1995
			JP 6099306 B	07-12-1994
			JP 61210031 A	18-09-1986
			NZ 215313 A	26-02-1990
			PH 25455 A	01-07-1991
			PT 82117 A,B	01-03-1986
			SG 50893 G	09-07-1993
			US 4956359 A	11-09-1990
			ZA 8601210 A	28-10-1987
			AU 599312 B	19-07-1990
			AU 5388886 A	04-09-1986
			CA 1294274 A	14-01-1992
			DK 36893 A	29-03-1993
			DK 90186 A	29-08-1986
			ES 552472 D	01-05-1987
			ES 8802300 A	16-07-1988
			GR 860531 A	24-06-1986
			IL 77995 A	30-06-1989
			IN 162808 A	09-07-1988
			JP 1965814 C	25-08-1995
			JP 6099386 B	07-12-1994
			JP 61205254 A	11-09-1986
			NZ 215312 A	26-02-1990
			PH 25525 A	24-07-1991
			PT 82118 A,B	01-03-1986
			US 5183902 A	02-02-1993
			US 5151418 A	29-09-1992
			US 5068231 A	26-11-1991
			ZA 8601215 A	29-10-1986
WO 0107043	A	01-02-2001	NONE	
WO 9937612	A	29-07-1999	AU 2287499 A	09-08-1999
			EP 1049672 A	08-11-2000
WO 9937614	A	29-07-1999	AU 2178199 A	09-08-1999
			EP 1049671 A	08-11-2000